J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmaker

Kyle LaHucik

Senior Reporter

It took one month for Johnson & Johnson to secure its $14 billion acquisition of Intra-Cellular Therapies, according to new securities filings that shed light …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmaker

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Arvinas, Pfizer’s PROTAC data fall short of hype in breast cancer

FDA’s medical review departments remain untouched (for now) by Musk’s cuts

Bristol Myers buys out cell therapy partner 2seventy bio

Corrected: Merck opens billion-dollar US facility to make Gardasil

Merck scores a win in Gardasil cases after judge says plaintiffs’ evidence ‘falls far short’

Obesity drug development—still room to grow

J&J, In­tra-Cel­lu­lar quick­ly sealed $14B deal as three oth­ers passed on buy­ing the neu­ro drug­mak­er

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Arv­inas, Pfiz­er’s PRO­TAC da­ta fall short of hype in breast can­cer

FDA’s med­ical re­view de­part­ments re­main un­touched (for now) by Musk’s cuts

Bris­tol My­ers buys out cell ther­a­py part­ner 2sev­en­ty bio

Cor­rect­ed: Mer­ck opens bil­lion-dol­lar US fa­cil­i­ty to make Gar­dasil

Mer­ck scores a win in Gar­dasil cas­es af­ter judge says plain­tiffs’ ev­i­dence ‘falls far short’

Obe­si­ty drug de­vel­op­ment—still room to grow

J&J, Intra-Cellular quickly sealed $14B deal as three others passed on buying the neuro drugmaker

Arvinas, Pfizer’s PROTAC data fall short of hype in breast cancer

FDA’s medical review departments remain untouched (for now) by Musk’s cuts

Bristol Myers buys out cell therapy partner 2seventy bio

Corrected: Merck opens billion-dollar US facility to make Gardasil

Merck scores a win in Gardasil cases after judge says plaintiffs’ evidence ‘falls far short’

Obesity drug development—still room to grow